Thank you. That is something we've always believed. The reason I ask is that there is some literature being put out, particularly through some lobbying by the Canadian Chamber of Commerce, which is making some people believe that if we were to establish national pharmacare, this would lead to a lot of untoward drawbacks for small business. One of the statements they made—and this was from a policy resolution of the Canadian Chamber of Commerce—was that if we make cost the main focus instead of access, we will decrease the development of new drugs. Does that make any sense to you?
On November 6th, 2018. See this statement in context.